A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon.
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 07 Feb 2013 Actual initiation date changed from Sep 2008 to Jul 2008 as reported by ClinicalTrials.gov.
- 28 Jan 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 28 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.